# Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

> **NCT02741128** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 133 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever
- Human Immunodeficiency Virus

## Interventions

- **BIOLOGICAL:** CYD Dengue Vaccine
- **BIOLOGICAL:** Placebo (NaCl 0.9%) vaccine group

## Key facts

- **NCT ID:** NCT02741128
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-06
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-01-19
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741128, "Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02741128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*